RAJAVITHI HOSPITAL
🇹🇭Thailand
- Country
- 🇹🇭Thailand
- Ownership
- Private
- Established
- 1951-01-01
- Employees
- -
- Market Cap
- -
Pregnancy Outcome and Vitamin D Level Among Vitamin D Supplementation During Pregnancy
Phase 3
Completed
- Conditions
- Pregnancy Outcome Among Vitamin D Supplementation During Pregnancy
- Interventions
- Drug: Placebo drug
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- Rajavithi Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04591847
- Locations
- 🇹🇭
Rajavithi hospital, Bangkok, Thailand
Study of Abobotulinum Toxin Versus Neubotulinum Toxin Injection For Hemifacial Spasm in Thai Patients
Phase 3
Not yet recruiting
- Conditions
- Hemifacial Spasm
- Interventions
- Drug: Injection botulinum toxin A ( Dysport 100 unit or Neuronox 33.33 unit)
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Rajavithi Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04589364
- Locations
- 🇹🇭
Rajavithi Hospital, Bangkok, Thailand
🇹🇭Lampang Hospital, Lampang, Thailand
🇹🇭Surat Thani hospital, Surat Thani, Thailand
Neubotulinum Toxin Injection in Cerivical Dystonia
Phase 3
Completed
- Conditions
- Cervical Dystonia
- Interventions
- Drug: Neuronox ® Injection
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Rajavithi Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04582929
- Locations
- 🇹🇭
Rajavithi Hospital, Bangkok, Thailand
🇹🇭Lampang Hospital, Lampang, Thailand
🇹🇭Suratthani Hospital, Surat Thani, Thailand
Efficacy and Safety of Bolus Comparing With Continuous Drip of 3% NaCl in Patients With Severe Symptomatic Hyponatremia.
Not Applicable
- Conditions
- HyponatremiaOsmotic Demyelination Syndrome
- Interventions
- Other: 3%NaCl
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- Rajavithi Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04561531
- Locations
- 🇹🇭
Rajavithi Hospital, Bangkok, Thailand
Sublingual vs Intrauterine MISOPROSTOL Plus Oxytocin Infusion for Prevention of Post-cesarean Hemorrhage in High Risk Pregnant Women: A Double-blind Placebo RCT
Phase 3
Completed
- Conditions
- To Compare Efficacy Intrauterine vs Sublingual MISOPROSTOL in Addition to Oxytocin in Reducing Blood Loss of Post-cesarean Section in High Risk Women
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- Rajavithi Hospital
- Target Recruit Count
- 135
- Registration Number
- NCT04560218
- Locations
- 🇹🇭
Rajavithi hospital, Bangkok, Thailand
Compare Outcome of Enhanced Recovery After Cesarean Surgery and Conventional Care
Not Applicable
Completed
- Conditions
- To Determine Whether ERAS Can Reduce Length of Stay in Pregnant Women After Cesarean Section
- Interventions
- Procedure: ERAS
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Rajavithi Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04530851
- Locations
- 🇹🇭
Rajavithi hospital, Bangkok, Thailand
A Comparison of Urinary Incontinence During Third Trimester of Nulliparous on Pelvic Floor Muscle Training
Not Applicable
Completed
- Conditions
- Urinary Incontinence
- Interventions
- Other: PFMTOther: non PFMT
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- Rajavithi Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT04525846
- Locations
- 🇹🇭
Rajavithi Hospital, Bangkok, Thailand
The Effect of Entonox on Stages of Labor in Nulliparous Women
Not Applicable
Completed
- Conditions
- ENTONOXDuration of LaborNulliparous
- Interventions
- Drug: EntonoxDrug: Not receive Entonox
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Rajavithi Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04321642
- Locations
- 🇹🇭
Rajavithi Hospital, Bangkok, Thailand
Fight COVID-19 Trial
Phase 3
Completed
- Conditions
- SARS-COV-2 InfectionsCOVID-19
- Interventions
- Drug: Oral
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Rajavithi Hospital
- Target Recruit Count
- 320
- Registration Number
- NCT04303299
- Locations
- 🇹🇭
Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand
Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis
Phase 3
Completed
- Conditions
- Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Rajavithi Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT04232423
- Locations
- 🇹🇭
Rajavithi hospital, Bangkok, Thailand